Patient recovery is closely linked with engagement and progressive programme completion.
Six patients died from progressive disease before completion of three treatment cycles.
Indeed, for all patients who had a complete resolution of clinical disease and whose microbiological culture results were negative for M. tuberculosis at 6-month treatment completion, a progressive decline of IFN-γ release was seen and the baseline positive QFT-G result had turned negative.
Serum Ca125 started increasing 4 months following treatment completion with progressive disease confirmed on CT (1/2008).
There has been one death in the subject with progressive disease at the completion of ABVD.
Treatment was given until progressive disease (or until completion of the planned 24 weeks of therapy), unacceptable toxicity or patient refusal.
All patients have discontinued treatment for the following reasons: progressive disease (n=9 patients), completion of treatment (n=9 patients), consent withdrawn (n=2 patients) and neutropaenia (n=2 patients).
Of the remaining seven patients, chemotherapy was interrupted before completion for progressive disease or worsening of disease symptoms (5 cases), for patient's refusal (1) and for prolonged toxicity (1).
This is followed by a pulse in expression of many TE families in the 4−8 hr and 8−12 hr embryo time points, followed by a progressive decrease through the completion of embryogenesis, and then an increase in expression in the late larvae and pupae, which may reflect expression in the developing germline.
Of the remaining 16 patients, chemotherapy was interrupted before the completion for progressive disease or worsening of disease symptoms (six cases, 14%), for patient's refusal (one patient, 2%), for surgical treatment (four patients, 10%), and for unacceptable toxicity (five patients: four grade 4 haematological toxicity (10%) and one grade 3 heart rhythm).
Is progress necessarily progressive?
